or Try an Advanced Search...

    Nephritis Stocks List

    Symbol Grade Name % Change
    AUPH A Aurinia Pharmaceuticals Inc 1.53
    BIIB F Biogen Idec Inc. -0.12
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Immunosuppressants Lupus Lupus Nephritis Medicine Alzheimer's Disease Autoimmune Disease Autoimmune Disorders Biopharmaceutical Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia Idiopathic Pulmonary Fibrosis Immune Disorders

    Related ETFs - A few ETFs which own one or more of the above listed Nephritis stocks.

    Symbol Grade Name Weight
    BIS C ProShares UltraShort Nasdaq Biotechnology 6.12
    PBE C PowerShares Dynamic Biotech & Genome 4.77
    BBH D Market Vectors Biotech ETF 4.15
    MNTL D Tema Neuroscience and Mental Health ETF 3.48
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 3.39
    View all Nephritis ETFs...
    Compare ETFs
    Compare BIS to FTXH Compare MNTL to FTXH Compare PBE to MNTL

        Nephritis Stocks Recent News

        Date Stock Title
        Nov 1 BIIB Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
        Nov 1 BIIB Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
        Oct 31 BIIB Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
        Oct 31 BIIB Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch
        Oct 31 BIIB Biogen slips as Morgan Stanley downgrades on Leqembi launch
        Oct 31 BIIB Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...
        Oct 30 BIIB Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
        Oct 30 AUPH Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
        Oct 30 BIIB Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
        Oct 30 BIIB Biogen and Neomorph enter molecular glue degrader deal
        Oct 30 BIIB Biogen (BIIB) Q3 2024 Earnings Call Transcript
        Oct 30 BIIB Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
        Oct 30 BIIB Biogen raises 2024 EPS guidance with strong Q3 results
        Oct 30 BIIB Biogen Inc. 2024 Q3 - Results - Earnings Call Presentation
        Oct 30 BIIB Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.
        Oct 30 BIIB SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
        Oct 30 BIIB Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say
        Oct 30 BIIB Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
        Oct 30 BIIB Biogen, Sage admit a defeat in major depression
        Oct 30 BIIB Biogen raises annual earnings guidance, tops Q3 estimates; shares up
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Immunosuppressants Lupus Lupus Nephritis Medicine Alzheimer's Disease Autoimmune Disease Autoimmune Disorders Biopharmaceutical Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia Idiopathic Pulmonary Fibrosis Immune Disorders
        Nephritis

        Nephritis is inflammation of the kidneys and may involve the glomeruli, tubules, or interstitial tissue surrounding the glomeruli and tubules.

        More about Nephritis
        Browse All Tags